作为 中国医药 行业的龙头企业—— 石药集团 (01093.HK)正面临着前所未有的挑战。2月25日晚间,公司发布盈利预警,预计2024年归母净利润将同比下滑约26%。这一消息引发市场关注,股价持续承压。截至2月25日收盘,石药集团报5.03港元,市值缩水至581亿港元,较2024年10月的阶段性高点已下跌超30%。集采冲击业绩,成药业务承压石药集团2024年业绩下滑的核心原因在于成药业务的营收...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.